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Abstract
Rules, whether in the form of norms, taboos or laws, regulate and coordinate human life. Some rules, however, are arbitrary
and adhering to them can be personally costly. Rigidly sticking to such rules can be considered maladaptive. Here, we test
whether, at the neurobiological level, (mal)adaptive rule adherence is reduced by oxytocin—a hypothalamic neuropeptide
that biases the biobehavioural approach-avoidance system. Participants (N¼139) self-administered oxytocin or placebo
intranasally, and reported their need for structure and approach-avoidance sensitivity. Next, participants made binary deci-
sions and were given an arbitrary rule that demanded to forgo financial benefits. Under oxytocin, participants violated the
rule more often, especially when they had high need for structure and high approach sensitivity. Possibly, oxytocin damp-
ens the need for a highly structured environment and enables individuals to flexibly trade-off internal desires against exter-
nal restrictions. Implications for the treatment of clinical disorders marked by maladaptive rule adherence are discussed.
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Introduction
Human societies rely on rules that enable individuals to predict
what others will do, and to avoid activities that are considered
socially inadequate, poorly appreciated or even deviant. Rules
come in many different forms. Examples include widely shared
taboos like the prohibition of incest or homicide, norms like
being fair and honest or society specific laws like driving on the
right side of the street. Adhering to rules ensures individuals to
be included rather than excluded from groups and societies
(Tyler, 1997), fulfils an epistemic need for predictability and
structure (Szechtman and Woody, 2004; Merwin et al., 2010) and
enables individuals to coordinate with others and to construct-
ively regulate social life.
Notwithstanding its functionality to both individuals and
their groups, obediently and mindlessly following rules can
also be maladaptive and dysfunctional. First, obediently follow-
ing rules undermines the individual’s ability to adapt to chang-
ing circumstances, to adequately solve new problems and to
seize on emerging opportunities (Wertheimer, 1945). Second,
sometimes rules are arbitrary and following them benefits nei-
ther the individual nor society. Classic illustrations include
Milgram’s obedience-to-authority experiments (Milgram, 1963),
where many participants obeyed the experimenter’s rule to
administer ostensibly painful electric shocks to another indi-
vidual, and Asch’s work showing that individuals often follow
majority opinions that are obviously wrong (Bond and Smith,
1996).
Interestingly, maladaptive rule adherence is also a trade-
mark of diverse clinical disorders, including obsessive compul-
sive disorder, anorexia nervosa and autism spectrum disorder,
in which individuals rigidly obey to often self-imposed and
highly arbitrary rules (Lewis and Bodfish, 1998; Szechtman and
Woody, 2004; Merwin et al., 2010). A promising hypothesis in the
literature is that these different psychopathologies share a def-
icit in oxytocin at the neurophysiological level (Modahl et al.,
1998; Kim et al., 2014; Hofmann et al., 2015). Here we examine
the possibility that oxytocin conditions adherence to arbitrary
rules that hurt self-interest without providing clear benefits.
Evidence for such a possibility would further our understanding
of the biological underpinnings of (mal)adaptive rule following,
and point to possible treatments of the aforementioned clinical
disorders and related psychopathologies.
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Oxytocin is a nine-amino acid produced in the hypothal-
amus, that functions as both a hormone and neurotransmitter
(Gimpl and Fahrenholz, 2001). Upon its release from the hypo-
thalamus, oxytocin affects a wide array of areas of the central
nervous system, including the brainstem, hippocampus, amyg-
dala and the striatum (Bethlehem et al., 2013). In addition to its
well-known role in reproduction and pair-bond formation
(Donaldson and Young, 2008), more recent work suggests that
oxytocin acts on (i) the cortico-amygdala circuitry to reduce
withdrawal from (social) threat, permitting alternative re-
sponses to danger than flight and submission (Kemp and
Guastella, 2011; Striepens et al., 2012; Harari-Dahan and
Bernstein, 2014), and (ii) the ‘wanting’ mesocorticolimbic cir-
cuitry promoting approach behaviour especially when targets
or events have positive valence (Lukas et al., 2011; Harari-Dahan
and Bernstein, 2014; Meziane et al., 2015).
Because of these psychobiological pathways we expected
oxytocin to reduce rule adherence. First, rules often demand the
restriction of spontaneous approach behaviour. For example,
waiting in front of a red traffic light or standing in a queue in
the supermarket interferes with the internal goal to proceed to-
wards one’s destination, or to not waste more time than strictly
necessary. The oxytocin-biased biobehavioural approach might
thus manifest itself in enhanced salience of appealing internal
goals and reduced fear for possible sanctions that may follow
from failure to adhere to a rule. The net result would be that in-
dividuals given oxytocin, rather than placebo, adhere less to ar-
bitrary rules that are personally costly to follow. Second, there
is some evidence that in healthy individuals, oxytocin increases
divergent thinking and creative performance by violating the
usual pattern and norm (De Dreu et al., 2014) and in patients
diagnosed with autistic spectrum disorder, oxytocin has been
shown to reduce the need for structure expressed by obsessive
ordering and repetitive behaviour (Hollander et al., 2003;
Anagnostou et al., 2014).
Our main prediction is therefore grounded in the idea that
oxytocin biases biobehavioural approach, and reduces need for
structure. While both approach and need for structure can be
state-dependent, there is good evidence that individuals also
differ in chronic approach (vs avoidance) sensitivity (Spielberg
et al., 2011), as well as in their personal need for structure, order
and preference for a predictable environment (Neuberg and
Newsom, 1993). Whereas individuals with heightened approach
sensitivity have a relatively flexible processing style for whom
set-switching is relatively easy (Baas et al., 2008), those with
high personal need for structure are relatively rigid in their
thinking and relying on tried-and-true rules and schemata
(Rietzschel et al., 2007). Accordingly, following the logic of a
moderation-of-process design (Spencer et al., 2005), oxytocin
should reduce rule following especially among individuals scor-
ing high on approach sensitivity, and high on personal need for
structure. Evidence for such treatment-by-trait interactions
would resonate with the more general observation that oxyto-
cin effects often depend on personality differences (Bartz et al.,




Predictions were tested in a randomized double-blind placebo
controlled between-subjects experiment. The experiment was
approved by the University of Amsterdam ethics committee
(file WOP-2015-4100) and complied with Helsinki protocols and
the APA-ethics guidelines. Subjects filled out a medical screen-
ing, provided written informed consent prior to participation
and received remuneration along with a written debriefing
upon completion of the study.
Statistical power and sample size
There is some concern about the robustness and replicability of
oxytocin effects on human behaviour (Nave et al., 2015; Walum
et al., 2016). One reason is that, as in many other (neuropharma-
cology) studies, many experiments on oxytocin have rather low
sample sizes and comparatively low statistical power. For ex-
ample, the median sample size across 40 human intranasal oxy-
tocin studies investigating the influence of oxytocin on a variety
of psychological processes like trust, emotion recognition and
face recognition was 49 participants (with the largest sample
size being n¼ 112; Van IJzendoorn and Bakermans-Kranenburg,
2012; Shahrestani et al., 2013; Van IJzendoorn, 2013; Nave et al.,
2015; Walum et al., 2016). In addition to a parsimonious experi-
mental setup with only one outcome variable (rule following,
see below), we recruited a larger sample size compared to previ-
ous studies (Walum et al., 2016). Specifically, we aimed to test
our predictions with a statistical power of b¼ 0.80 (and a¼ 0.05).
In estimating the required sample size, we used a recent study
from our own laboratory in which we used similar procedures,
considered a similar type of effect (‘divergent thinking’ the gen-
eration of ideas that deviate from an implicit prime) and studied
subjects from a similar population (albeit a few years earlier,
the composition of the research population tends to remain
relatively stable). This study was Experiment 4 in De Dreu et al.
(2014) and had an gp
2¼0.061 with N¼ 62. G-Power 3.1 (Faul et al.,
2007) indicated a required sample size of N¼ 123. Because De
Dreu et al., (2014) relied on male participants only, and oxytocin
effects in females may be weaker due to their higher concentra-
tions of endogenous oxytocin, we recruited a sample of 139
undergraduate students (mean age¼ 21.5 6 3.4, 99 female) for
this study. Participants were randomly assigned to treatment
conditions. There was no systematic difference in the sex pro-
portions across treatments (v2-test (1)¼ 0.52, P¼ 0.47).
The study was advertised as a study on ‘medication and de-
cision making’ via the Research Institute’s on-line recruiting
system. Participants filled out an on-line medical screening.
Exclusion criteria were significant medical or psychiatric illness,
medication, smoking more than five cigarettes per day and drug
or alcohol abuse. Eligible subjects were scheduled for a session
and instructed to refrain from smoking or drinking (except for
water) for 2 h before the experiment.
Medication
Participants self-administered a single intranasal dose of 24 IU
of oxytocin (Syntocinon spray; Novartis; three puffs per nostril,
each with 4 IU of oxytocin) or placebo 30 min before the start of
the experimental tasks (for similar procedures and rationale,
see e.g. Baumgartner et al., 2008; De Dreu et al., 2010; Stallen
et al., 2012). To avoid any subjective effects (for example, olfac-
tory effects) other than those caused by oxytocin, the placebo
contained all of the active ingredients except for the neuropep-
tide (De Dreu et al., 2010). Thus, the only difference between the
placebo and treatment was the absence versus presence of the
active neuropeptide.
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Experimental procedure
Figure 1 summarizes the timeline and experimental tasks. Upon
arriving at the laboratory, subjects were seated in individual cu-
bicles in front of a computer. After signing the informed consent
forms subjects were instructed to self-administer the medica-
tion under experimenter supervision. Neither the participant
nor the experimenter knew about the medication type (placebo
or oxytocin). Although there are several possible pathways
through which intranasal oxytocin affects brain and behaviour
(Born et al., 2002; Gossen et al., 2012; Striepens et al., 2013; Leng
and Ludwig, 2016), research typically finds effects 30 min post-
administration. Accordingly, we followed the procedure used
before in our own lab and that of others (Baumgartner et al.,
2008; De Dreu et al., 2010). After administration subjects pro-
ceeded for 30 min with a series of personality and state ques-
tionnaires. More specifically, and because oxytocin has been
implicated in fear modulation (Kirsch et al., 2005; Labuschagne
et al., 2010), subjects reported their current anxiety level (STAI;
Spielberger and Sydeman, 1994). The state STAI is a 20 item
questionnaire asking respondents to rate statements like ‘I am
tense’ or ‘I feel calm’ on a 4-point Likert scale (1¼not at all, to
4¼very much so). The scale had a good internal consistency in
our sample (Cronbach a¼ 0.89). They then responded to Dutch
translations of questionnaires measuring behavioural inhib-
ition and behavioural approach tendencies (BIS-BAS; Carver and
White, 1994), and need for structure (PNS: Kivim€aki et al., 1996).
If time remained, they were provided with the 60-item NEO-
questionnaire which measures five broad dimensions of
personality (Hofstee et al., 1995; Denissen et al., 2008). Because
items were administered randomly and none of the subjects
completed the entire measure before the 30-min loading time
was finished, data were incomplete and further ignored.
BIS-BAS is a 24 item questionnaire with items like ‘I worry
about making mistakes’ (behavioural inhibition) or ‘I often act
on the spur of the moment’ (behavioural approach) (1¼very
false for me, to 5¼ very true for me). The BAS-scale can further
be divided into three subscales. Since the focus of this study
was approach sensitivity as a general construct, and to prevent
multiple testing of the same hypothesis, the BAS score was not
further subdivided into subscale-scores. Both BIS and BAS had
good internal consistencies in our sample (BIS: Cronbach
a¼ 0.83, BAS: Cronbach a¼ 0.80). PNS is a 12 item questionnaire
in which participants rate items like ‘I enjoy being spontaneous’
(low structural need) or ‘I find that a consistent routine enables
me to enjoy life more’ (high structural need) on a 6-point scale
(1¼ strongly disagree, to 6¼ strongly agree; Cronbach a¼ 0.81).
The computer was configured to switch to the experimental
task only 30 min after administration. In this decision-making
task, participants saw 30 balls on the computer screen. They
had to drag each ball individually in either the blue or yellow
bucket with their mouse. In the instructions, it was explained to
them that for each ball they put in the blue bucket they would
receive 0.05e and for each ball they put in the yellow bucket
they would receive 0.10e. Then they read that ‘the rule is to put
the balls in the blue bucket’. Above each bucket there was a
counter showing the amount of money already accumulated
(Kimbrough and Vostroknutov, 2015). Thus, subjects would
maximize their payoff by putting all balls in the yellow bucket.
Yet completely adhering to the rule would earn them only half
of the money they could earn would they consistently violate
this rule. No reason was given for following the rule and partici-
pants would not face any negative consequences for violating
the rule.
Data analytic strategy
Compared to most studies on intranasal oxytocin (Walum et al.,
2016), we only test the effect of intranasal oxytocin on one out-
come variable, thereby avoiding the risk of false positive effects
due to treatment comparisons across multiple outcome vari-
ables in one sample. Predictions were tested in a single regres-
sion model, with rule following (number of balls in the blue
bucket) as criterion and as predictors main effects for treatment
(0¼placebo; 1¼oxytocin), BIS-BAS and PNS, as well as the two-
way interactions between treatment on the one hand and BIS-
BAS and PNS on the other. Significant two-way interactions
were probed using simple slope analyses for treatment at 61
s.d. of the critical trait (Aiken and West, 1999). To facilitate inter-
pretation of interactions, and to reduce possible multicollinear-
ity, all continuous variables were mean-centred. Because of the
censoring of the dependent variable, we performed censored re-
gression but note that using a linear OLS regression model did
not alter the statistical conclusions reported here. Significance
was decided with P 0.05 (two-tailed) and only in case of pre-









3-5 min> 30 min
Fig. 1. Timeline of the experiment. After self-administration of either placebo or oxytocin participants waited for at least 30 min before receiving instructions for the
rule-task. In the rule task, each ball has to be dragged into either the blue or the yellow bucket. The rule is to put each ball into the blue bucket, which only yields e0.05
per ball, whereas putting a ball into the yellow bucket yields e0.10.
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tailed). In light of the on-going debate about the robustness of
intranasal oxytocin effects on human behaviour, we further cor-
rected all hypothesized regression main effects and interactions
for multiple comparisons using false discovery rate (FDR;
Benjamini and Hochberg, 1995) to reduce the probability of type
I errors. We also checked whether obtained results were robust
to control variables like age, sex, type of contraception and hor-
monal cycle. Types of contraception were obtained through
self-report in the medical screening. Female participants further
indicated their first and last day of their last menstruation from
which luteal and follicular phase were inferred.
Results
As the rule following task is relatively new and few studies used
it, in a first analysis, we probed the general tendency for oxyto-
cin to influence rule following over and beyond individual dif-
ferences in approach sensitivity and need for structure. Figure 2
shows that, first of all, rule following in our sample is varied,
with only few participants strictly following the (arbitrary) rule
and only few subjects disobeying completely. Most participants
tried to find some middle-ground between strict compliance
and complete disobeying, and thus sometimes did, and some-
times did not follow the rule. Furthermore, as can also be seen
in Figure 2, oxytocin treatment appeared to influence rule fol-
lowing. While 33% of the sample decided to adhere fully to the
rule in the placebo condition by placing all balls in the bucket
that would only yield half of the payment, only 22% did so in
the oxytocin condition. On the other extreme, 11% of the partici-
pants in the oxytocin condition violated the rule maximally by
putting all balls in the bucket they were not supposed to. Only
5% of the participants did so in the placebo condition (overall
univariate effect of oxytocin on rule adherence: Mann–Whitney
U¼ 2797, P¼ 0.08).
To examine the proposed trait-interaction responsible for
oxytocin-reduced rule-following, we computed a censored re-
gression model with rule following as the criterion and treat-
ment (dummy coded 0¼placebo; 1¼oxytocin), BIS, BAS, PNS
and the interactions among treatment and personality traits as
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Fig. 2. Rule following. Share of participants in the oxytocin (blue) and placebo (black) condition as a function of how many of the 30 balls have been placed according to
the rule.


































Fig. 3. Moderators of rule following. Rule following depending on (A) behavioural inhibition (BIS), (B) behavioural approach (BAS) and (C) need for structure (PNS) in the
oxytocin treatment (blue dots) and placebo treatment (black dots). Lines indicate the best linear fit.
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Obtained P-values for the main treatment effect and the three
interaction terms were FDR-corrected to reduce the probability
of type I errors.
Results are summarized in Table 1. There was no significant
interaction of rule following and behavioural inhibition, regard-
less of treatment (Figure 3A and Table 1; b(BIS)¼ 0.41, t¼ 0.13,
P¼ 0.90, two-sided; b(treatmentBIS)¼ 1.10, t¼ 0.24, P¼ 0.81).
Second, and as predicted, subjects with high behavioural ap-
proach sensitivity violated the rule more frequently when given
oxytocin (Figure 3B and Table 1; b(treatmentBAS)¼12.76,
t¼2.34, P¼ 0.04). Post-hoc probes of this interaction
(Holmbeck, 2002) revealed that under oxytocin the higher the
behavioural approach sensitivity, the more often the rule was
violated (b¼8.12, t ¼ 1.97, P¼ 0.04); under placebo, there was
no significant change in rule violation across behavioural ap-
proach sensitivity (b¼ 4.64, t¼ 1.28, p¼ 0.20). This fits the hy-
pothesis that oxytocin biases biobehavioural approach, and
suggests that oxytocin further activates and accelerates inher-
ent tendencies towards behavioural approach.
From the fitted regression line shown in Figure 3B, it may ap-
pear as if participants with very low approach sensitivity are
more rule-following under oxytocin than placebo. However, we
note that such an inference is problematic, as most participants
reported behavioural approach scores between 3 and 5. Finally,
whereas individuals under placebo adhered more to the rule
the higher their need for structure (Table 1; b(PNS)¼ 6.13,
t¼ 2.21, P¼ 0.03), oxytocin dampened rule adherence in particu-
lar in participants high on need for structure (Figure 3C and
Table 1; b(treatmentPNS)¼9.15, t¼2.50, P¼ 0.04). In par-
ticipants with a high need for structure, oxytocin thus led to
more rule breaking. This was confirmed by post-hoc probes of
this interaction (Holmbeck, 2002). While need for structure sig-
nificantly predicted higher rule-following under placebo
(b¼ 6.13, t¼ 2.21, P¼ 0.03), this was not the case under oxytocin
(b¼3.01, t¼1.21, P¼ 0.23).
Robustness checks
Since personality traits have been measured directly after intra-
nasal oxytocin administration, we cannot rule out the possibil-
ity that these measures were already influenced by early
psychophysiological effects of the oxytocin administration. We
therefore tested for possible effects of treatment on behavioural
approach, behavioural inhibition, need for structure and state
anxiety. Table 2 shows the means and standard deviations.
Participants in the oxytocin group did not significantly differ in
either of the four traits/state from participants in the placebo
group (t-tests, BAS: t(137)¼ 0.10, P¼ 0.92; BIS: t(137)¼ 0.47,
P¼ 0.64; PNS: t(137)¼0.47, P¼ 0.64; STAI: t(137)¼0.88,
P¼ 0.38). Looking at the correlational structure among the per-
sonality measures, it appeared that participants with high be-
havioural inhibition or low behavioural approach were also
more likely to report a high need for structure (Table 2).
Administration of oxytocin can differentially affect the be-
haviour of males and females (Rilling et al., 2014; Yao et al., 2014)
and might interact with menstrual cycle and usage of contra-
ceptives. Accordingly, we performed additional analyses to test
the robustness of the reported results using stepwise inclusion
of further control variables. Again, obtained P-values were FDR-
corrected to reduce the type I error probability. First, we tested
whether the effect of oxytocin on rule-following is sex specific,
by allowing for an interaction of sex and drug-treatment on
rule-following in the regression model (column 2, Table 3).
There was no significant sex (b¼6.04, P¼ 0.11) or sexdrug
interaction (b¼ 2.67, P¼ 0.65) in our sample. Also when entering
the interaction terms between personality traits and treatment,
there was no sex effect of oxytocin on rule following (column 3,
Table 3), showing that the observed effect of oxytocin on rule-
following was not significantly moderated by sex in our sample.
Note however that most of our sample was comprised of female
participants.
Since hormonal spiral and the use of birth control pill, as
well as the menstrual cycle might affect the hormonal balance
and moderate the effect of oxytocin on behaviour in female par-
ticipants, we also included the type of contraception female
participants used in our sample (column 4, Table 3) and the
menstrual cycle (column 4, Table 3) together with all possible
first-order interactions of drug treatment and these controls.
The reported interactions between personality traits and oxyto-
cin on rule-following are robust to these controls (columns 4
and 5, Table 3).
Discussion and conclusions
When given oxytocin, rather than matching placebo, individ-
uals were less likely to follow an arbitrary rule that demanded
them to forgo financial benefits. Consistent with the propos-
ition that oxytocin reduces the demand for a structured envir-
onment and increases approach sensitivity (Kemp and
Guastella, 2011; Harari-Dahan and Bernstein, 2014), we found
that oxytocin reduced rule following especially among
Table 1. Censored (below 0 and above 30) regression results predict-
ing the propensity of rule adherence (i.e. the number of balls put
into the blue bucket) as a function of treatment and personality
traits (mean-centred)
B SE t P 
Intercept 22.93 2.15 10.68 0.01
Treatment1,a 3.97 2.71 1.47 0.19
Sex2 2.78 3.23 0.86 0.39
Age 0.41 0.44 0.94 0.35
State Anxiety (STAI) 3.01 2.68 1.12 0.26
Behavioural Inhibition (BIS) 0.41 3.13 0.13 0.90
Behavioural Approach (BAS) 4.64 3.61 1.28 0.20
Need for Structure (PNS) 6.13 2.77 2.21 0.03
TreatmentBISa 1.10 4.53 0.24 0.81
TreatmentBASa 12.76 5.45 2.34 0.04
TreatmentPNSa 9.15 3.66 2.50 0.04
1Note: 0¼placebo, 1¼oxytocin; 0¼ female, 1¼male.
aFDR corrected P-value.
Table 2. Descriptive statistics and zero-order correlations for person-
ality traits, broken down by treatment
Placebo Oxytocin
M (s.d.) M (s.d.) 1. 2. 3. 4.
STAI 2.08 (0.49) 2.16 (0.55) – 0.23 0.14 0.15
BIS 3.54 (0.72) 3.47 (0.81) – 0.30 0.55
BAS 3.81 (0.53) 3.80 (0.54) – 0.41
PNS 3.79 (0.82) 3.86 (1.03) –
Note: STAI = State Anxiety, BIS = Behavioural Avoidance, BAS = Behavioural
Approach, PNS = Need for Structure.
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individuals with high need for structure, and high approach
sensitivity.
Findings fit earlier work that oxytocin up-regulates creative
thinking and reduces convergent processing (De Dreu et al.,
2014). Yet they may appear at odds with work showing that oxy-
tocin promotes social conformity, which can be seen as a ten-
dency to follow rather than ignore social rules (Stallen et al.,
2012; also see Ma et al., 2014; Edelson et al., 2015). The key differ-
ence between the current study and those on creativity, and the
work on social conformity, is that the rule in this study was ar-
bitrary and adhering to it had no benefits for either oneself or
another group. In contrast, following the majority view within
one’s group has a range of consequences to both oneself (e.g.
being included in the group, benefitting from the ‘wisdom of the
crowd’) and the group one affiliates with (e.g. fostering coordin-
ation and joint action). Possibly then, oxytocin enables individ-
uals to focus on the benefits and costs of a particular rule,
allowing them to flexibly adapt by either following the rule or
complying with a norm, or not.
Recently, Shalvi and De Dreu, (2014) found that oxytocin did
not increase financially beneficial lying in a die rolling task. Lying
can be interpreted as violating a rule and, as such, their finding
may seem at odds with the current observation that oxytocin
reduced rule adherence (given certain traits). However, lying argu-
ably entails a higher psychological cost to the self-image (Shalvi
et al., 2011; Gneezy et al., 2013; Abeler et al., 2014) and carries a
moral dimension that is much less salient for arbitrary rules. As
noted in Shalvi and De Dreu (2014; also see Shalvi et al., 2011), it re-
quires additional justifications—such as that lying benefits one’s
group rather than just oneself—to violate a morally laden rule
such as ‘thou shall not lie’. Absent the need for such additional
justification, we see that, especially for individuals with high
approach sensitivity and need for structure, oxytocin appears to
increase behavioural flexibility (also see De Dreu et al., 2014), sug-
gesting that oxytocin reduces adherence to arbitrary rules that do
not much more than hurting self-interest, and boosts adherence
to rules that facilitate the regulation of social life.
A key finding was that effects of oxytocin emerged especially
in subjects with high need for structure and high approach sen-
sitivity. This not only fits the general observation that effects of
oxytocin are strongly contingent on a broad range of states and
traits (Bartz et al., 2011a), but also resonates with work suggest-
ing that several clinical disorders, such as autism spectrum dis-
order, obsessive compulsive disorder and anorexia nervosa,
seem to share important deficits in the oxytocinergic system.
Low levels of oxytocin in blood plasma and the cerebrospinal
fluid have been associated with autism spectrum disorder
(Modahl et al., 1998), obsessive compulsive disorder (Leckman
et al., 1994) and anorexia nervosa (Demitrack et al., 1990).
Without exception these disorders are marked by rigid adher-
ence to self-imposed rules, that seem arbitrary from an outside
perspective, like arranging objects according to certain rules
(Lam and Aman, 2006), or following harsh dietary restrictions
(Garner and Bemis, 1982). In autism spectrum disorder and an-
orexia nervosa, treatment with oxytocin has some positive ef-
fects: it up-regulates social approach in autistic patients (Andari
et al., 2010; Anagnostou et al., 2014), and reduces biased atten-
tion to palliative food items in patients with anorexia nervosa
(Kim et al., 2014). Accordingly, present results suggest that treat-
ing these patients with oxytocin may reduce at least one crit-
ical, mostly maladaptive and often overlooked tendency—the
rigid following of rules that have no clear function.
It is important to note that the effect of oxytocin, particular
in participants with high trait approach sensitivity, might also
Table 3. Censored (below 0 and above 30) regression results predicting the propensity of rule adherence (i.e. the number of balls put into the
blue bucket) with stepwise included control variables
(1) (2) (3) (4) (5)
B (P) B (P) B (P) B (P) B (P)
Intercept 22.59 (0.00) 24.48 (0.00) 23.84 (0.00) 18.31 (0.00) 18.00 (0.00)
Treatment1,a 4.72 (0.08) 5.79 (0.07) 5.33 (0.14) 0.57 (0.92) 1.05 (0.84)
Sex2 6.04 (0.11) 5.27 (0.26) – –
Treatment  Sex 2.67 (0.65) 4.36 (0.51) – –
BIS 1.04 (0.76) 0.54 (0.87) 1.10 (0.75)
BAS 4.61 (0.20) 4.20 (0.26) 4.04 (0.29)
PNS 6.35 (0.02) 6.16 (0.02) 6.37 (0.02)
Treatment  BISa 2.49 (0.60) 3.15 (0.70) 3.46 (0.67)
Treatment  BASa 14.07 (0.02) 12.19 (0.06) 11.99 (0.07)
Treatment  PNSa 9.69 (0.02) 9.43 (0.04) 9.00 (0.07)
STAI 3.29 (0.23) 3.93 (0.16)
Age 0.46 (0.30) 0.46 (0.32)
Contraception (Pill) 5.49 (0.26) 3.72 (0.58)
Contraception (Hormonal Spiral) 5.43 (0.32) 4.08 (0.52)
Treatment  Pill 5.01 (0.47) 2.64 (0.81)
Treatment  Hormonal Spiral 8.03 (0.29) 1.69 (0.87)
Follicular Phase 0.64 (0.92)
Luteal Phase 5.63 (0.39)
Treatment  Follicular Phase 7.62 (0.44)
Treatment  Luteal Phase 12.90 (0.21)
Note. 10¼placebo, 1¼oxytocin; 20¼ female, 1¼male. Contraception: all female participants indicated either to use the pill or a hormonal spiral—male participants are
therefore coded as baseline.
aFDR corrected P-value.
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bear negative consequences. For example, Bartz et al. (2011b)
and Ebert et al. (2013) found that the administration of intra-
nasal oxytocin to participants with borderline personality dis-
order—characterized by emotional instability and
impulsiveness—led to less trusting and cooperative behaviour
(also see Simeon et al., 2011). Together with the present results,
these findings may point to an inverted U-shape relationship
between oxytocin and rigid rule following on the one hand,
and extreme emotional stability and impulsiveness on the
other. With individuals rigidly following (arbitrary) rules, ex-
ogenous oxytocin may enable them to respond more flexibly;
yet in individuals with a propensity for impulsivity, exogenous
oxytocin may undermine adaptiveness and lead to flexibility
that is erratic and maladaptive. It is noteworthy that a similar
inverted U-shape has been noted between cognitive control
and dopamine (Cools and D’Esposito, 2011; Piray et al., 2015), a
neurochemical with strong connections to the oxytocinergic
circuitry (Carter, 2014; De Dreu et al., 2014; also see Van
Wimersma Greidanus et al., 1990). Future work is therefore
needed to investigate the possible positive and negative conse-
quences of intranasal oxytocin administration on rule-
adherence in particular in clinical populations that are charac-
terized by impulsiveness on the one side and rigid behaviour
on the other side.
This study is the first to explore the connection of oxytocin
and maladaptive rule adherence using a novel rule-following
task. By recruiting a larger sample size than previous human
oxytocin studies (Walum et al., 2016) in combination with a sim-
ple and straightforward task, testing our hypotheses on only
one dependent variable and correcting results for multiple com-
parisons, we hope to at least partly address current concerns in
the literature about a potentially high rate of false positive find-
ings of intranasal oxytocin on human social behaviour
(McCullough et al., 2013; Nave et al., 2015; Walum et al., 2016).
However, as with any novel paradigm, our results should be
seen as an early exploratory finding that warrants further repli-
cation, especially since our main finding rests on a treatment-
by-trait interaction, that requires more statistical power to reli-
ably detect than a simple main effect (Open Science
Collaboration, 2015).
Although rules—including taboos, norms and laws—often
are functional and needed for the regulation of human life,
mindlessly adhering to any rule may be maladaptive and hurt-
ful to oneself. Here we provided first evidence that in healthy
individuals (maladaptive) rule adherence is attenuated by oxy-
tocin, especially when individuals have high need for structure,
and strong approach sensitivity.
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